H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth

The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life. A considerable portion of patients however display intrinsic resistance to Cfz. Our mechanistic unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Min Jae, Miller, Zachary, Park, Ji Eun, Bhattarai, Deepak, Lee, Wooin, Kim, Kyung Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411724/
https://www.ncbi.nlm.nih.gov/pubmed/30858500
http://dx.doi.org/10.1038/s41598-019-40635-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411724/
https://www.ncbi.nlm.nih.gov/pubmed/30858500
http://dx.doi.org/10.1038/s41598-019-40635-1

Ejemplares similares